Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (TIPI)

• ClinicalTrials.gov Identifier: NCT04070443
• Recruitment Status: Recruiting
• First Posted: August 28, 2019
• Last Update Posted: December 10, 2021
• Sponsor: Centre Leon Berard
• Information provided by (Responsible Party): Centre Leon Berard

Tracking Information

• First Submitted Date: July 19, 2019
• First Posted Date: August 28, 2019
• Last Update Posted Date: December 10, 2021
• Actual Study Start Date: November 13, 2019
• Estimated Primary Completion Date: June 1, 2029 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 26, 2019)

Impact of Ponatinib induction treatment on the TFR rate [ Time Frame: 36 months after initiation of ponatinib ]

Rate of patients reaching a stable MR4.5 (BCR-ABL (IS) ≤0.0032% with at least 32,000 copies of ABL) for ≥ 2 years at Month 36 after initiation of ponatinib.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: August 26, 2019)

• Clinical activity of the proposed therapeutic strategy [ Time Frame: up to 24 months after ponatinib initiation ]
  For all patients : Rate of patients with MR4.5; MR4.0 and MMR at 1, 2, 3, 6, 9, 12, 24 months after ponatinib initiation
• Clinical activity of the proposed therapeutic strategy [ Time Frame: up to 6 months after ponatinib initiation ]
  For all patients : Rate of patients with a BCR-ABL/ABL (IS) ≤ 10% and rate of patients with CCyR (or its molecular equivalent, BCR-ABL/ABL (IS) ≤ 10%) at 3 and 6 months after ponatinib initiation.
• Clinical activity of the proposed therapeutic strategy [ Time Frame: from the first intake of Ponatinib until one of this criteria is reached, assessed up to 5 years ]
  For all patients : Time to MR4.5, MR4.0 or MMR following ponatinib initiation
• Clinical activity of the proposed therapeutic strategy [ Time Frame: from the first intake of Ponatinib until one of this criteria is reached, assessed up to 5 years ]
  For all patients : Duration of MR4.5, MR4.0 or MMR
• Clinical activity of the proposed therapeutic strategy [ Time Frame: from the date of inclusion until the date of the first progression or date of death from any cause, whichever came first, assessed up to 5 years ]
  For all patients : Progression Free survival
• Clinical activity of the proposed therapeutic strategy [ Time Frame: From the date of inclusion until the date of death from any cause, whichever came first, assessed up to 5 years ]
  For all patients : Overall survival
• Clinical activity of the proposed therapeutic strategy [ Time Frame: 3, 6, 9, 12 and 24 months after imatinib cessation ]
  For patients reaching TFR criteria and following imatinib cessation: Rate of successful TFR (patients sill with MR4.5) at 3, 6, 9, 12 and 24 months after imatinib cessation
• Clinical activity of the proposed therapeutic strategy [ Time Frame: from imatinib cessation until the date of progression/relapse, whichever came first, assessed up to 5 years ]
  For patients reaching TFR criteria and following imatinib cessation: Duration of TFR after imatinib cessation.
• Clinical activity of the proposed therapeutic strategy [ Time Frame: From the date of imatinib cessation until the date of death from any cause, assessed up to 5 years ]
  For patients reaching TFR criteria and following imatinib cessation: OS after imatinib cessation
• Clinical activity of the proposed therapeutic strategy [ Time Frame: from the date of imatinib cessation until the date of the first progression or date of death from any cause, whichever came first, assessed up to 5 years ]
  For patients reaching TFR criteria and following imatinib cessation: PFS after imatinib cessation
• Clinical activity of the proposed therapeutic strategy [ Time Frame: from the date of ponatinib initiation until the onset of the following events: loss of responses, accelerated phase or blast crisis at any time, death at any time from any cause; drug discontinuation due to adverse events, assessed up to 5 years ]
  For patients reaching TFR criteria and following imatinib cessation: Event-free survival according ELN recommendations
• Clinical activity of the proposed therapeutic strategy [ Time Frame: from the date of imatinib cessation until 30 days after the last study drugs intake or until initiation of a new anti-cancer treatment, whichever came first, assessed up to 5 years ]
  For patients reaching TFR criteria and following imatinib cessation: Rate of TKI-withdrawal syndrome after Imatinib cessation
• Clinical activity of the proposed therapeutic strategy [ Time Frame: from the date of imatinib re introduction until date of MMR or MR4.5, assessed up to 5 years ]
  For patients reaching TFR criteria and following imatinib cessation: Rate of MMR, MR4.0 and MR4.5 recovery in case of imatinib re-introduction (
• Incidence of Adverse Events of the proposed therapeutic strategy [ Time Frame: from the signature of the ICF and the first intake of study drug until 30 days after the last study drugs intake or until initiation of a new anti-cancer treatment, assessed up to 5 years ]
  • Hematologic and non-hematologic AEs graded according to the NCI CTCAE v5.0
  • Incidence of arterial thrombotic events during the induction phase and during the consolidation phase.
• Quality of Life (QLQ-CML24 questionnaire) [ Time Frame: At screening, at each visit from Month 1 to Month 60 (if applicable) and then during the TFR phase and at STSV 30 days, assessed up to 5 years ]
  Evolution of Quality of life according to QLQ-CML24 questionnaire.
• Quality of Life (QLQ-C30 questionnaire) [ Time Frame: At screening, at each visit from Month 1 to Month 60 (if applicable) and then during the TFR phase and at STSV 30 days, assessed up to 5 years ]
  Evolution of Quality of life according to QLQ-C30 questionnaire.
• Ponatinib pharmacokinetics (non-decisional) [ Time Frame: At screening, at each visit from Month 6 (induction phase) ]
  Plasma concentrations of ponatinib over the 6 months of the induction period.
• Patient' compliance to the proposed therapeutic strategy [ Time Frame: At each visit during induction and consolidation phase ]
  Compliance to ponatinib and imatinib as evaluated using the Morisky medication adherence scale questionnaire

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
• Official Title: A Multicentre, Open-label Phase II Trial Evaluating the Safety and Efficacy of Ponatinib Induction Followed by Imatinib Maintenance in Adult Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) ≤ 65 Years

Brief Summary

The investigators hypothesize that, in newly diagnosed de novo chronic phase CML patients, an induction treatment with ponatinib for 6 months should increase the rate of patients reaching a stable MR4.5 allowing cessation of imatinib treatment.

The investigators proposal is to conduct a multicenter, Phase II trial to evaluate the safety, clinical and biological activity of an induction treatment with ponatinib for 6 months, followed by a consolidation treatment with imatinib in newly diagnosed de novo chronic phase CML patients.

Detailed Description

TREATMENT PLAN :

All eligible patients will be treated:

• During the induction Phase (Month 1 to Month 6) with ponatinib (30mg/day) single agent; then
• During the consolidation Phase (Month 7 to Month 36) with imatinib (400mg/day) single agent; then

• From M36 :

  • Patients with stable MR4.5 (i.e. since at least 2 years) will enter in the TFR phase and will stop imatinib treatment. Thereafter, in case of MMR loss, imatinib will be re-introduced as per investigator judgement (including for dose).
  • Patients without stable MR4.5 will continue imatinib treatment until stable MR4.5, or M60, PD, death, withdrawal of consent or overall trial completion. Such patients will be allowed to enter into the TFR phase as soon as a stable 2-year MR4.5 is reached: however, they will be considered as a failure for the primary endpoint analysis.

STATISTICS :

A total of 170 patients will be enrolled in this study.

According to a Fleming design, with a P0=20% as minimal efficacy rate and P1=30% as an expected target, 156 patients should be enrolled, assuming an unilateral type I error alpha of 5% and 90% power. At the time of analysis, if at least 40 successes are observed among the 156 evaluable patients, the treatment will be considered as interesting for further investigation in this indication. Considering that some patients may withdraw their consent before 36 months (about 10%), the investigators plan to enrol 170 patients in total.

DATA ENTRY, DATA MANAGEMENT AND STUDY MONITORING All the data concerning the patients will be recorded in the electronic case report form (eCRF) throughout the study. Serious adverse event (SAE) and Adverse Event of Specific Interest (AESI) reporting will be also paper-based by e-mail and/or Fax.

The sponsor will perform the study monitoring and will help the investigators to conduct the study in compliance with the clinical trial protocol, Good Clinical Practices (GCP) and local law requirements.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Philadelphia Chromosome Positive CML
• BCR-ABL Positive Chronic Myelogenous Leukemia

Intervention

• Drug: Ponatinib
  30mg/day; 6 months. Dose adaptation procedures are planned in case of toxicity.
• Drug: Imatinib
  400 mg/day; at least 30 months (M7 to M36), then depending of MR4.5 . Dose adaptation procedures are planned in case of toxicity.

Study Arms

Experimental: Induction phase with Ponatinib followed by Imatinib

Ponatinib (Iclusig®) : Tyrosine Kinase Inhibitor (BCR-ABL); oral (tablets) : 30mg/day during 6 months (induction phase); Takeda & Incyte Biosciences.

Imatinib (either Glivec® or any generic form) : Tyrosine Kinase Inhibitor (BCR-ABL, ABL, KIT and PDGFRA receptor tyrosine kinases); oral : 400 mg/day during at least 30 months (then, depending of MR4.5)

Interventions:

• Drug: Ponatinib
• Drug: Imatinib

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: August 26, 2019): 170
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: June 1, 2029
• Estimated Primary Completion Date: June 1, 2029 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Male or female patients aged ≥18 and ≤65 years at time of inform consent signature.

• Cytologically confirmed CML, Philadelphia chromosome positive with or without additional chromosomal abnormalities and/or BCR-ABL positive (Major BCR (M-BCR) transcript exclusively), i. e. Cryptic Philadelphia chromosome patients can be enrolled:

  • diagnosed within the past 3 months prior to D1 (i.e. within 60 days [± 7 days] since the date of first cytogenetic analysis),
  • in chronic phase defined by i) <15 % blasts in peripheral blood and bone marrow, ii) < 30% blast plus promyelocytes in peripheral blood and bone marrow; iii) < 20 % basophils in peripheral blood and iv) ≥100 X 109 platelets/L in peripheral blood,
  • no extra-medullary disease.
  • All EUTOS long-term survival Scores.
• No prior treatment for CML with any tyrosine kinase inhibitor (eg. imatinib, dasatinib, nilotinib or bosutinib), or busulphan; interferon-alpha; homoharringtonine; cytosine arabinoside; or any other investigational agent; with the exception of hydroxyurea and/or anagrelide which are the only authorized prior treatments.

Note: Hydroxyurea should be stopped at least 24 hours prior the initiation of ponatinib.

• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1 or 2.
• Adequate organ functions as defined below according to lab tests performed within 7 days before Day 1:

Renal function:

- Serum creatinine clearance ≥ 50 mL/min/1.73m2 according to CKD-EPDI formula or serum creatinine ≤ 2 upper limit of normal (ULN).

Hepatic function:

• Serum bilirubin < 1.5 × ULN, with the following exception: Patients with known Gilbert disease who have serum bilirubin level ≤ 3 ULN may be enrolled.
• Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase ≤ 2.5 ULN.

• Amylase or Lipase ≤ 1.5 × ULN Total cholesterol ≤1.5 ULN

  • Women of child-bearing potential must have a negative serum pregnancy test within 7 days before study drug start and must agree to use an effective form of contraception from the time of the negative pregnancy test up to 3 months after the last dose of study treatments.
  • Fertile men must agree to use an effective method of contraception during the study and for up to 3 months after the last dose of study treatments.
  • Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
  • Patients must be covered by a medical insurance.

Exclusion Criteria:

• Any form of prior auto- or allo-hemopoietic stem cell transplant.
• Hypersensitivity to the active substance or to any of the excipients of ponatinib and imatinib (see respective IB/SmPC).
• Inability to take oral medication including malabsorption syndrome or other illness that could affect oral absorption of the study treatments (hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption).

• Patients using, or requiring to use while on the study of any not permitted concomitant medications:

  • Any approved anti-cancer systemic treatment including chemotherapy, targeted therapy, immunotherapy or any biological therapy,
  • Any investigational agents,
  • Any treatment able to induce " torsades de pointes ",
  • Any strong inducers and inhibitors of CYP3A4.
• Patients with a malignancy other than CP-CML within 5 years prior to Day 1 with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated in situ carcinoma of the cervix, basal or squamous cell skin cancer, localised prostate cancer or ductal in situ carcinoma treated surgically with curative intent).
• Patients with active B or C hepatitis infection. Notes: Patients with past Hepatitis B Virus (HBV) infection or resolved HBV infection (defined as having a negative hepatitis B surface antigen (HBsAg) test and a positive hepatitis B core antibody (HBcAb) test) are eligible.

Patients with a positive HBcAb test must have a negative HBV DNA test at screening.

Patients positive for Hepatitis C Virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.

• Patients with significant cardiovascular disease, such as New York Heart Association cardiac disease Class II or greater, myocardial infarction within 3 months prior to D1, unstable arrhythmias, unstable angina, peripheral arterial occlusive disease, venous thromboembolism or pulmonary embolism, brain stroke, evolutive ischemic cardiopathy; prolonged corrected QT interval (QTc) interval on baseline electrocardiogram (>450 msec on the Fridericia's correction) despite correction of predisposants factors; long congenital QT syndrome.

• Any of the following medical conditions despite adequate therapeutic management:

  • Uncontrolled HTA despite adequate ongoing treatment.
  • Diabetes with documented target organ damage.
• Pregnant or lactating women.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 65 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Franck-Emmanuel NICOLINI, MD; 04 78 78 28 28; franck-emmanuel.nicolini@lyon.unicancer.fr

• Listed Location Countries: France

Administrative Information

• NCT Number: NCT04070443
• Other Study ID Numbers: ET18000120 (TIPI)
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Centre Leon Berard
• Original Responsible Party: Same as current
• Current Study Sponsor: Centre Leon Berard
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Franck-Emmanuel NICOLINI, MD; Centre Leon Berard

• PRS Account: Centre Leon Berard
• Verification Date: July 2021